JP5774610B2 - パーキンソン病の治療方法 - Google Patents

パーキンソン病の治療方法 Download PDF

Info

Publication number
JP5774610B2
JP5774610B2 JP2012555453A JP2012555453A JP5774610B2 JP 5774610 B2 JP5774610 B2 JP 5774610B2 JP 2012555453 A JP2012555453 A JP 2012555453A JP 2012555453 A JP2012555453 A JP 2012555453A JP 5774610 B2 JP5774610 B2 JP 5774610B2
Authority
JP
Japan
Prior art keywords
carbidopa
entacapone
levodopa
formulation
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012555453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013521263A (ja
Inventor
ロウル、ユハ
クオッパメキ、ミッコ
エルメン、ユハ
メンニステ、ペッカ
Original Assignee
オリオン コーポレーション
オリオン コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリオン コーポレーション, オリオン コーポレーション filed Critical オリオン コーポレーション
Publication of JP2013521263A publication Critical patent/JP2013521263A/ja
Application granted granted Critical
Publication of JP5774610B2 publication Critical patent/JP5774610B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012555453A 2010-03-04 2011-03-03 パーキンソン病の治療方法 Active JP5774610B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31039810P 2010-03-04 2010-03-04
US61/310,398 2010-03-04
US41282110P 2010-11-12 2010-11-12
US61/412,821 2010-11-12
US201161438416P 2011-02-01 2011-02-01
US61/438,416 2011-02-01
PCT/FI2011/000013 WO2011107653A2 (en) 2010-03-04 2011-03-03 Method for treating parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015094429A Division JP2015180644A (ja) 2010-03-04 2015-05-01 パーキンソン病の治療用医薬

Publications (2)

Publication Number Publication Date
JP2013521263A JP2013521263A (ja) 2013-06-10
JP5774610B2 true JP5774610B2 (ja) 2015-09-09

Family

ID=44065577

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012555453A Active JP5774610B2 (ja) 2010-03-04 2011-03-03 パーキンソン病の治療方法
JP2015094429A Pending JP2015180644A (ja) 2010-03-04 2015-05-01 パーキンソン病の治療用医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015094429A Pending JP2015180644A (ja) 2010-03-04 2015-05-01 パーキンソン病の治療用医薬

Country Status (14)

Country Link
US (4) US20130137729A1 (enExample)
EP (1) EP2542220B1 (enExample)
JP (2) JP5774610B2 (enExample)
KR (1) KR101868326B1 (enExample)
CN (1) CN102781424B (enExample)
AU (1) AU2011222856B2 (enExample)
BR (1) BR112012018256A8 (enExample)
CA (1) CA2784819C (enExample)
EA (1) EA026419B1 (enExample)
ES (1) ES2614179T3 (enExample)
IL (1) IL221744A (enExample)
MX (1) MX336187B (enExample)
WO (1) WO2011107653A2 (enExample)
ZA (1) ZA201205836B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015180644A (ja) * 2010-03-04 2015-10-15 オリオン コーポレーション パーキンソン病の治療用医薬

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
WO2008094053A1 (en) 2007-01-31 2008-08-07 Bial-Portela & Ca, S.A. Dosage regimen for comt inhibitors
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
KR102023255B1 (ko) 2009-04-01 2019-09-19 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
BR112014014341A2 (pt) 2011-12-13 2017-08-22 Bial Portela & Ca Sa Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
CN104884064A (zh) 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
US9642810B2 (en) 2013-03-15 2017-05-09 Mylan Inc. Formulation containing carbidopa, levodopa, and entacapone
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
EP3696182A1 (en) * 2015-08-27 2020-08-19 Prexton Therapeutics SA Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
IL277553B2 (en) * 2018-03-23 2024-11-01 Lobsor Pharmaceuticals Ab Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
CN112741808B (zh) * 2019-10-29 2024-02-06 南京济群医药科技股份有限公司 一种提高含盐酸苄丝肼口服固体组合物稳定性的方法
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
US20230181493A1 (en) * 2020-04-10 2023-06-15 Senda Biosciences, Inc. Biomarkers related to parkinson's disease and methods of using the same
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3462536A (en) 1960-07-22 1969-08-19 Merck & Co Inc Method of inhibiting decarboxylase
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US20080076825A1 (en) 2003-12-31 2008-03-27 Thomas Bader Novel Crystalline Forms of Entacapone and Production Thereof
DK1751087T3 (da) 2004-06-04 2012-07-16 Xenoport Inc Levodopa-derivater og sammensætninger og anvendelser deraf
US20060241183A1 (en) * 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
ATE444746T1 (de) * 2005-06-08 2009-10-15 Orion Corp Eine herstellungsmethode von entacapon- enthaltenden granulaten für orale dosierformen
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
NZ565460A (en) * 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
DK1959948T3 (da) 2005-12-05 2012-08-20 Xenoport Inc Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
US8741342B2 (en) 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
WO2009108077A2 (en) 2008-02-28 2009-09-03 Bial - Portela & Ca., S.A. Pharmaceutical composition for poorly soluble drugs
ES2476792T3 (es) * 2008-08-22 2014-07-15 Wockhardt Limited Composición farmacéutica de dosis oral unitaria única que comprende levodopa, carbidopa y entacapona o sales de las mismas
NZ591326A (en) * 2008-08-22 2012-12-21 Wockhardt Research Center An extended release pharmaceutical composition of entacapone or salts thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
CA2784819C (en) * 2010-03-04 2018-02-13 Orion Corporation Use of levodopa, carbidopa and entacapone for treating parkinson's disease
JP5551001B2 (ja) 2010-06-22 2014-07-16 株式会社Ｐｆｕ 摩擦係数推定装置および摩擦係数推定方法
JP2015006373A (ja) * 2014-07-14 2015-01-15 株式会社大都技研 遊技台

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015180644A (ja) * 2010-03-04 2015-10-15 オリオン コーポレーション パーキンソン病の治療用医薬

Also Published As

Publication number Publication date
US20210085635A1 (en) 2021-03-25
IL221744A (en) 2016-11-30
WO2011107653A3 (en) 2011-11-03
BR112012018256A2 (enExample) 2011-09-09
BR112012018256A8 (pt) 2017-12-19
MX2012010161A (es) 2012-10-03
AU2011222856A1 (en) 2012-07-26
ES2614179T3 (es) 2017-05-30
KR20130006638A (ko) 2013-01-17
CA2784819A1 (en) 2011-09-09
CN102781424A (zh) 2012-11-14
WO2011107653A8 (en) 2012-08-02
US11771675B2 (en) 2023-10-03
US10857120B2 (en) 2020-12-08
EA201290865A1 (ru) 2013-02-28
US12521363B2 (en) 2026-01-13
HK1177896A1 (zh) 2013-08-30
EP2542220B1 (en) 2016-11-02
JP2013521263A (ja) 2013-06-10
CN102781424B (zh) 2016-03-30
CA2784819C (en) 2018-02-13
AU2011222856B2 (en) 2015-10-15
MX336187B (es) 2016-01-07
WO2011107653A2 (en) 2011-09-09
US20150150839A1 (en) 2015-06-04
US20240050394A1 (en) 2024-02-15
EA026419B1 (ru) 2017-04-28
KR101868326B1 (ko) 2018-06-19
US20130137729A1 (en) 2013-05-30
EP2542220A2 (en) 2013-01-09
ZA201205836B (en) 2014-01-29
JP2015180644A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
US12521363B2 (en) Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
JP5336181B2 (ja) 経口投薬形態
JP6033373B2 (ja) レボドパの放出制御製剤及びその使用
ES2606463T3 (es) Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada
CN104902880A (zh) 包含氢吗啡酮和纳洛酮的药物组合物
JP2019189645A (ja) Ｃｎｓ化合物の安定化製剤
JP5138932B2 (ja) モダフィニルの改変された放出の製薬学的組成物
WO2014171542A1 (ja) 放出制御製剤
JP6061924B2 (ja) 口腔内分散性製剤
US20150037405A1 (en) Pharmaceutical compositions of levodopa and carbidopa
KR101761983B1 (ko) 구강내 속붕해 필름 조성물 및 그 제조방법
HK1177896B (en) Use of levodopa, carbidopa and entacapone for treating parkinson's disease
ES2804348T3 (es) Formulaciones de liberación controlada de levodopa y usos de las mismas
KR20250073694A (ko) 데페리프론을 포함하는 변형 방출 약제학적 제제

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140718

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20140718

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140919

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141022

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150501

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150630

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150701

R150 Certificate of patent or registration of utility model

Ref document number: 5774610

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250